Literature DB >> 12673680

Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers.

Mei Y Yu1, Joanna H M Tong, Paul K S Chan, Tin L Lee, Michael W Y Chan, Anthony W H Chan, Kwok W Lo, Kai F To.   

Abstract

Loss of heterozygosity (LOH) at chromosome 3p21 is frequent in cervical cancers. The candidate tumor suppressor gene, RASSF1A located at 3p21.3, is found to be inactivated in several major human cancers, implicating its significance in carcinogenesis. We aimed to investigate the status of RASSF1A in cervical cancers. The mutation and methylation status of RASSF1A were analysed in 4 cervical cancer cell lines, 50 primary cervical cancers including 33 squamous cell carcinoma (SCC), 17 adenocarcinoma (AC) and 11 normal controls. The primary cancer samples were also detected for LOH at 3p21 and human papillomavirus (HPV). Hypermethylation of RASSF1A was detected in 30% of SCC, 12% of AC and in 1 of the 4 cancer cell lines but was absent in all normal cases. Methylation of the cancer cell line was associated with loss of gene expression, which was restored by demethylation. About 67% (8 of 12) of hypermethylated primary cancers showed concomitant LOH at 3p21. No somatic mutation was found in all primary cancer samples or cell lines but 2 cases showed germline polymorphism at codon 133. Oncogenic HPV DNAs were found in most cancer samples. No correlation was detected between RASSF1A-hypermethylation or LOH at 3p21 and age of patient, HPV genotype, tumor grade and stage. Hypermethylation of RASSF1A occurs in a subset of cervical cancers, among which concomitant LOH at 3p21 is common. The results supported that RASSF1A may be one of the cervical cancer-related tumor suppressor genes located at 3p21 regions. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673680     DOI: 10.1002/ijc.11051

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Cullin-4A·DNA damage-binding protein 1 E3 ligase complex targets tumor suppressor RASSF1A for degradation during mitosis.

Authors:  Lingyan Jiang; Rong Rong; M Saeed Sheikh; Ying Huang
Journal:  J Biol Chem       Date:  2011-01-04       Impact factor: 5.157

2.  DNA methylation and carcinogenesis of PRDM5 in cervical cancer.

Authors:  Hai-Yan Cheng; Xiu-Wei Chen; Li Cheng; Yun-Duo Liu; Ge Lou
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-06       Impact factor: 4.553

Review 3.  DNA methylation in endometrial cancer.

Authors:  Meng Hua Tao; Jo L Freudenheim
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

4.  Alterations in gene promoter methylation and transcript expression induced by cisplatin in comparison to 5-Azacytidine in HeLa and SiHa cervical cancer cell lines.

Authors:  Swati Sood; Radhika Srinivasan
Journal:  Mol Cell Biochem       Date:  2015-03-14       Impact factor: 3.396

Review 5.  Aberrant DNA methylation in malignant melanoma.

Authors:  Carolina Schinke; Yongkai Mo; Yiting Yu; Kathy Amiri; Jeff Sosman; John Greally; Amit Verma
Journal:  Melanoma Res       Date:  2010-08       Impact factor: 3.599

Review 6.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

Review 7.  Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science.

Authors:  Nicolas Wentzensen; Mark E Sherman; Mark Schiffman; Sophia S Wang
Journal:  Gynecol Oncol       Date:  2008-12-02       Impact factor: 5.482

8.  DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer.

Authors:  Gopinathan Gokul; Bhimana Gautami; Surapaneni Malathi; A Pavani Sowjanya; Usha Rani Poli; Meenakshi Jain; Gayatri Ramakrishna; Sanjeev Khosla
Journal:  Epigenetics       Date:  2006-12-07       Impact factor: 4.528

9.  The association between RASSF1 gene polymorphisms and lung cancer susceptibility among people in Hubei Province of China.

Authors:  Geqiong Xiao; Tao Zhang; Jie Yao; Jinghua Ren; Wenmiao Cao; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11

10.  RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression.

Authors:  Rosalyn R Ram; Saurabh Mendiratta; Brian O Bodemann; Michael J Torres; Ugur Eskiocak; Michael A White
Journal:  Mol Cell Biol       Date:  2014-04-14       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.